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BCR-ABL1 mutation development during ﬁrst-line treatment
with dasatinib or imatinib for chronic myeloid leukemia in
chronic phase
TP Hughes1, G Saglio2, A Quintás-Cardama3,9, MJ Mauro4, D-W Kim5, JH Lipton6, MB Bradley-Garelik7, J Ukropec7,9 and A Hochhaus8
BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as ﬁrst-line treatment of chronic
myeloid leukemia in chronic phase (CML-CP). Less is known about mutation development during ﬁrst-line treatment with dasatinib
and nilotinib, despite increased use because of higher response rates compared with imatinib. Retrospective analyses were
conducted to characterize mutation development in patients with newly diagnosed CML-CP treated with dasatinib (n= 259) or
imatinib (n= 260) in DASISION (Dasatinib versus Imatinib Study in Treatment-Naive CML-CP), with 3-year minimum follow-up.
Mutation screening, including patients who discontinued treatment and patients who had a clinically relevant on-treatment event
(no conﬁrmed complete cytogenetic response (cCCyR) and no major molecular response (MMR) within 12 months; ﬁvefold increase
in BCR-ABL1 with loss of MMR; loss of CCyR), yielded a small number of patients with mutations (dasatinib, n= 17; imatinib, n= 18).
Dasatinib patients had a narrower spectrum of mutations (4 vs 12 sites for dasatinib vs imatinib), fewer phosphate-binding loop
mutations (1 vs 9 mutations), fewer multiple mutations (1 vs 6 patients) and greater occurrence of T315I (11 vs 0 patients). This trial
was registered at www.clinicaltrials.gov as NCT00481247.
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INTRODUCTION
Chronic myeloid leukemia (CML) has become a manageable
chronic disease with the advent of BCR-ABL1 inhibitors;
however, mutations in the BCR-ABL1 gene may confer resistance
to inhibitors, potentially limiting their effectiveness against
expansion of speciﬁc leukemic clones.1–4 Although the BCR-
ABL1 inhibitor imatinib has demonstrated signiﬁcant efﬁcacy in
newly diagnosed patients with CML in chronic phase (CML-CP),
primary and secondary resistance to imatinib was observed (no
initial response or loss of an established response), resulting in
unfavorable long-term outcomes.5,6 Patients treated with
imatinib are susceptible to numerous mutations that reduce
the binding of imatinib,7–9 and BCR-ABL1 mutations may be
responsible for 9–48% of primary resistance and 10–68% of
secondary or acquired resistance to imatinib.10–13 Dasatinib,
nilotinib, bosutinib and ponatinib have enabled many patients,
including those with mutations, to overcome imatinib resis-
tance; however, each lack efﬁcacy against a small number of
different leukemic clones, and all except ponatinib lack efﬁcacy
against T315I.3,4,14–17
Dasatinib and nilotinib are also approved for the treatment of
newly diagnosed CML-CP patients in many countries.18–21
Compared with imatinib, dasatinib and nilotinib in the ﬁrst-
line setting are associated with faster and deeper molecular
responses and reduced risk of transformation to accelerated
phase/blast phase (AP/BP).22,23 Although a narrow spectrum of
mutations developing during imatinib treatment are known to
confer resistance to subsequent treatment with dasatinib
or nilotinib, less is known qualitatively or quantitatively
regarding the spectrum of mutations emerging during ﬁrst-line
treatment.3,4,24–26
The ﬁrst-line phase 3 trial DASISION (Dasatinib versus Imatinib
Study in Treatment-Naive CML-CP) demonstrated that dasatinib
signiﬁcantly improved early cytogenetic and molecular response
rates compared with imatinib in the treatment of newly
diagnosed CML-CP patients.23,24,27 With a minimum 2-year
follow-up in DASISION, mutational analyses in patients who
discontinued treatment for any reason identiﬁed 10 mutations
in each treatment arm affecting three amino acids in dasatinib-
treated patients and nine amino acids in imatinib-treated
patients.24
To identify patients potentially at higher risk for developing
mutations, mutational analyses based on a minimum 3-year
follow-up were conducted for patients in DASISION who had
discontinued treatment for any reason and for those on
treatment with clinically relevant events (deﬁned as no
conﬁrmed complete cytogenetic response (cCCyR) and no major
molecular response (MMR) within 12 months; a ﬁvefold increase
in BCR-ABL1 transcript levels with loss of MMR; loss of CCyR).
Potential relationships between the development of mutations,
response dynamics and long-term patient status were also
explored.
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SUBJECTS AND METHODS
DASISION (CA180-056; ClinicalTrials.gov: NCT00481247) is an ongoing,
open-label, phase 3 randomized trial for which patient characteristics and
eligibility criteria have been described.27 Brieﬂy, adults with cytogenetically
conﬁrmed Philadelphia chromosome-positive (Ph+) CML-CP diagnosed
within 3 months who had adequate hepatic and renal function and no
serious medical conditions were eligible. With the exception of anagrelide
or hydroxyurea, no prior CML therapy was permitted. The trial was
approved by all institutional review boards and ethics committees, and all
patients gave written informed consent before randomization in
accordance with the Declaration of Helsinki.
In the study, 519 patients with newly diagnosed CML-CP were
randomized 1:1 to dasatinib 100mg once daily (n=259) or imatinib
400mg once daily (n=260). With a two-sided α=0.05 and power of 90%,
518 subjects were needed to show a statistically signiﬁcant difference in
12-month CCyR rates between the two arms when the 12-month CCyR
rates in the imatinib 400mg once daily arm and the dasatinib 100mg once
daily arm were assumed to be 69% and 81%, respectively. Study treatment
was discontinued for protocol-deﬁned disease progression (increasing
white blood cell count, loss of complete hematologic response, loss of
major cytogenetic response, AP/BP criteria met, death from any cause
during treatment), treatment failure (no hematologic response at 3 months,
no complete hematologic response or cytogenetic response at 6 months,
no partial cytogenetic response at 12 months, no CCyR at 18 months),28
unacceptable toxicity, patient/investigator decision or pregnancy.
Treatment interruptions and dose reductions were permitted for
managing adverse events. Dose escalations to dasatinib 140mg once
daily or imatinib 600–800mg/day were permitted for suboptimal response
at 3–18 months.28 The primary end point was cCCyR rate by 12 months
(the conﬁrming assessment could be after 12 months). A cCCyR was
deﬁned as CCyR documented on two consecutive assessments at least
28 days apart. Key secondary end points included time in cCCyR, rates of
MMR, deﬁned as a BCR-ABL1 transcript level in peripheral blood on
international scale p0.1%, corresponding to ≥ 3-log reduction from the
standardized baseline, at any time, times to cCCyR or MMR and durations
of progression-free survival and overall survival. Transformation to AP/BP
was deﬁned according to the European LeukemiaNet (ELN) 2006 criteria
(clonal evolution was not included).28
Mutational analysis
In DASISION, BCR-ABL1 mutational analyses were to be conducted in all
patients receiving ﬁrst-line dasatinib or imatinib at baseline and the end of
treatment. Here, we also conducted BCR-ABL1 mutational analyses in the
subset of patients who were considered more likely to have a mutation
according to ELN recommendations.12 This analysis included patients on
treatment who had at least one clinically relevant event (no cCCyR within
12 months; no MMR within 12 months; ﬁvefold increase in BCR-ABL1
transcript levels with loss of MMR; loss of CCyR), and/or who discontinued
treatment for any reason (Table 1). Patients may have been included in
both categories having (1) a clinically relevant on-treatment event and
(2) discontinued treatment. Stored specimens taken closest to the event
were analyzed retrospectively for the presence of mutations (for patients
who discontinued treatment, samples were analyzed within 45 days,
before or after discontinuation). For those patients in whom a mutation
was identiﬁed, all stored specimens from baseline to the ﬁnal sample
collected were retrospectively analyzed for the presence of mutations.
Mutational analyses were conducted at a central independent laboratory
(MolecularMD, Portland, OR, USA) using direct sequencing on peripheral
blood samples after ampliﬁcation of the ABL tyrosine kinase domain
(amino acids 35–510) by reverse transcription PCR.29 When a mutation was
initially detected in a patient sample, repeat testing from the RNA was
performed to verify the presence of the identiﬁed mutation. Mutation data
were blinded for samples collected at baseline and end of treatment. The
remaining samples were analyzed retrospectively.
Molecular response
BCR-ABL1 transcript levels in peripheral blood were assessed using
quantitative real-time PCR by MolecularMD. Patients with typical BCR-
ABL1 transcripts b2a2 and b3a2 were eligible for molecular response
analysis. Data are expressed on the international scale.29,30
Patient status
For patients with mutations detected based on 3-year minimum follow-up,
status was assessed based on extended follow-up (minimum 4 years),
including BCR-ABL1 transcript level and current treatment dose for patients
still on treatment, and included survival status (alive or dead, reason for
death), current treatment and transformation to AP/BP for patients who
discontinued treatment.
RESULTS
After a 3-year minimum follow-up, 169 of 259 (65%) randomized
patients in the dasatinib arm and 194 of 260 (75%) in the imatinib
arm of the study were identiﬁed with events that warranted
mutational analysis (Table 2). BCR-ABL1 mutations were detected
in a minority of patients in both arms (dasatinib, n= 17/169 (10%);
imatinib, n= 18/194 (9%): Table 2 and Figure 1). Patients receiving
dasatinib had a more narrow spectrum of mutations (affecting
four sites) compared with those receiving imatinib (affecting 12
sites) and fewer phosphate-binding loop (P-loop) mutations
(1 (G250E) vs 9 (G250E, n=3; L248V, n=1; E255K/V, n=4; Y253H,
n= 1), respectively). The G250E mutation seen with dasatinib was
identiﬁed in a single patient sample collected 12 months after the
start of treatment and was not detected in samples collected
thereafter. The patient was screened owing to no MMR within
12 months and a ﬁvefold increase in BCR-ABL1 transcript level with
the loss of a subsequent MMR. His molecular and cytogenetic
responses subsequently improved following dose escalation to
140mg, and he remains on treatment as of last follow-up (44
years after start of treatment). Fewer patients on dasatinib (n= 1)
had two BCR-ABL1 mutations detected in tandem or as separate
clones compared with patients on imatinib (n= 6). The T315I
mutation was only identiﬁed in the dasatinib arm (n= 11).
Characteristics of patients with mutations
The majority of patients with mutations had their ﬁrst mutation
detected within 12 months of the start of treatment (Figure 2): in
the dasatinib arm, 65% (11/17) had a mutation detected within
Table 1. Triggers for mutational analysis: DASISION 3-year database
On-treatment, clinically
relevant events
Off-treatment, reason for discontinuation
from study
No conﬁrmed CCyR within
12 months
Disease progressiona





levels with loss of MMR





Subject request to discontinue
Abbreviations: CCyR, complete cytogenetic response; DASISION, Dasatinib
versus Imatinib Study in Treatment-Naive CML-CP; MMR, major molecular
response. aIncreasing white blood cell count, loss of complete hematologic
response (CHR), loss of major cytogenetic response, transformation to
accelerated phase/blast phase and death. bAny subject who received study
therapy and then discontinued treatment for intolerance (recurrent
≥grade 3 hematologic toxicity or ≥ grade 2 nonhematologic toxicity
despite dose reduction necessitating discontinuation of therapy) or
treatment failure (lack of hematologic response at 3 months, lack of CHR
or CyR at 6 months, lack of partial cytogenetic response at 12 months and
lack of CCyR at 18 months). cAs of last patient status; patients with interim
loss of CCyR who subsequently regained a CCyR were not included.
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12 months and 94% (16/17) had a mutation detected within
24 months (range, 3–30 months); in the imatinib arm, 67% (12/18)
had a mutation detected within 12 months and 72% (13/18) had a
mutation detected within 24 months (range, 5–36 months). In
addition, 76% (13/17) of dasatinib-treated patients and 61%
(11/18) of imatinib-treated patients had a mutation detected
shortly before the trigger for mutational analysis was observed
(p3 months prior). The majority of patients with mutations had
more than one of the deﬁned clinically relevant on-treatment
events, with most failing to achieve or maintain a molecular or
cytogenetic response (Table 3).
Among patients with mutations in the dasatinib arm, a greater
percentage had high baseline Euro (Hasford) scores (41%; Table 4)
compared with all randomized patients (19% high, 47–48%
intermediate and 33% low).27 In the dasatinib arm, Euro (Hasford)
scores among patients with T315I were evenly distributed (4 high,
3 intermediate and 4 low); however, among patients with other
mutations, more had high baseline scores (n= 3: 1 G250E, 1 V299L
and 1 V299L/F317I) than intermediate (n= 2: 1 F317L and 1 V299L)
or low (n= 1: F317L). Euro (Hasford) scores among patients with
mutations in the imatinib arm showed a similar distribution as for
all randomized patients (Table 4), with no clear trends with regard
to the incidence of speciﬁc mutations, double mutations or P-loop
mutations. Analysis of molecular and cytogenetic response
dynamics showed that most patients with mutations had little
or no initial response or experienced a transient modest response
often deep enough to achieve a CCyR but not an MMR (Table 4).
Long-term patient status
For patients with mutations identiﬁed based on 3-year minimum
follow-up, an extended 4-year minimum follow-up was con-
ducted. This extended follow-up of patients with mutations
showed poor outcomes regardless of treatment (dasatinib vs
imatinib) and high rates of treatment discontinuation (dasatinib,
E450G (n = 1)
M244V (n = 1)
E355G (n = 2)
L387M (n = 1)
F359C/I/V (n = 1,1,3)G250E (n = 3)
H396P (n = 1) E255K/V (n = 2,2)
D276G (n = 1)
L248V (n = 1)
M351T (n = 3)
T315I (n = 11)
F317I/L (n = 1,2)






Y253H (n = 1)
One patient had 2 mutations: 
V299L/F317I







Figure 1. Distribution of mutations detected in DASISION at 3 years by treatment arm and BCR-ABL1 location. *Identiﬁed in one sample




























Figure 2. Detection of mutations over time. Kaplan–Meier curve of
the detection of mutations for both dasatinib- and imatinib-treated
patients tested for mutations. Dasatinib-treated patients with
samples analyzed for mutations: n= 155; imatinib-treated patients
with samples analyzed for mutations: n= 183. Patients were
censored when they were no longer at risk for developing a
mutation.
Table 2. DASISION 3-year mutational analysis
Dasatinib 100 mg once daily,
N= 259
Imatinib 400 mg once daily,
N= 260
Patients identiﬁed for mutational analysis, n (%) 169 (65) 194 (75)
Patients with samples analyzed for mutations, n 155 183
Patients with samples not analyzed,a n 14 11
Patients with mutations detected (total), n 17 18
Mutations detectedb (n) G250E (1), V299L (3), T315I (11),
F317I/L (3)
M244V (1), L248V (1), G250E (3), Y253H (1), E255K/V (4), D276G (1),
M351T (3), E355G (2), F359C/I/V (5), L387M (1), H396P (1), E450G (1)
Abbreviation: DASISION, Dasatinib versus Imatinib Study in Treatment-Naive CML-CP. aAlternate transcript; BCR-ABL1 too low to test; other. bIncludes patients
with two mutations: one dasatinib (V299L/F317I) and six imatinib (L248V/E355G, E255V/E450G, E255K/M351T, Y253H/E255V, D276G/F359C and M351T/F359V).
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n= 14/17; imatinib, n= 14/18). The primary reason for discontinua-
tion of patients with mutations was protocol-deﬁned disease
progression (dasatinib, n= 11; imatinib, n= 8; Table 3). Of all
patients in DASISION who discontinued because of protocol-
deﬁned disease progression, patients with mutations accounted
for 61% on dasatinib (n= 11/18) and 42% on imatinib (n= 8/19).
The patients with mutations who discontinued because of
transformation to AP/BP (a subset of patients who discontinued
because of disease progression) all died: four dasatinib patients
(three who had T315I and one who had F317I) and three imatinib
patients (two mutations each: M351T/F359V, E255K/M351T and
D276G/F359C). The remaining deaths among patients with
mutations (dasatinib, infection, n= 2; imatinib, complication
following allogenic stem cell transplant, n= 1) were not related
to BCR-ABL1 inhibitor therapy. The one dasatinib patient with two
mutations (V299L/F317I) was the only patient with a mutation
identiﬁed who transformed to AP/BP after dasatinib discontinua-
tion; this patient had discontinued treatment because of loss of
complete hematologic response, transformed after switching to
nilotinib, then received allogeneic hematopoietic stem cell
transplantation and was alive at last follow-up. The remaining
three imatinib patients with two mutations discontinued treat-
ment because of poor cytogenetic response (two with no partial
cytogenetic response by 12 months, one with no major
cytogenetic response by 18 months), switched to dasatinib
(n= 2) or nilotinib (n= 1) and were alive at last follow-up.
Although most patients who had mutations detected were off
study at the time of this analysis, there were three patients in the
dasatinib arm and four patients in the imatinib arm who remained
on study treatment. The three patients with mutations in the
dasatinib arm who remained on treatment had a good molecular
response (BCR-ABL1 transcript levels p0.1% (MMR); Table 3);
however, the four patients with mutations in the imatinib arm
who remained on treatment had BCR-ABL1 transcript levels 41%
(Table 3). The presence of a mutation and the failure to achieve
BCR-ABL1 o1% represent treatment failure under the current ELN
recommendations and should lead to a switch to another
tyrosine-kinase inhibitor.12,31
DISCUSSION
This retrospective study based on 3-year minimum follow-up in
the DASISION trial showed that BCR-ABL1 mutations were
identiﬁed in only a small number of patients (dasatinib, n= 17;
imatinib, n= 18), even though the criteria for mutational analysis
were expanded from that used in previous reports of DASISION
(clinically relevant on-treatment events, discontinuation because
of any reason) to include a large number of patients in this
analysis. Consistent with results of in vitro studies and previous
ﬁndings in the second-line setting,3,32–38 a narrower spectrum of
mutations was detected in patients who received ﬁrst-line
dasatinib compared with imatinib. Notably, the number of
patients who carried more than one mutation was higher with
imatinib. Patients with more than one BCR-ABL1 mutation
generally have a poorer outcome compared with patients
harboring only one BCR-ABL1 mutation.39,40 In this mutational
analysis, all patients with two BCR-ABL1 mutations discontinued
study treatment (dasatinib, n= 1; imatinib, n= 6) either because of
protocol-deﬁned disease progression (dasatinib, n= 1; imatinib,
n= 3) or treatment failure (imatinib, n= 3), and 3 (imatinib)
subsequently died. Compared with dasatinib, more patients
treated with imatinib also had P-loop mutations. Mutations in
the P-loop of the BCR-ABL1 kinase domain have been shown to be
associated with poor prognosis.8
Table 3. Clinically relevant on-treatment events, reasons for discontinuation and current status in patients with mutations in DASISION
Dasatinib 100mg once daily,
n=17
Imatinib 400 mg once daily,
n= 18
Clinically relevant on-treatment events, na 14 16
No MMR within 12 months 12 16
No cCCyR within 12 months 8 12
Loss of CCyR 6 4
Fivefold BCR-ABL1 increase with loss of MMR 2 1
Discontinued treatment, n 14 14
Protocol-deﬁned disease progression 11 8
Lost MCyR 4 4
Transformed to AP/BP 4 3
Lost CHR 1 1
Increased WBC count 1 —
Death 1 —
Treatment failure 1 4
No PCyR, 12 months — 2
No CCyR, 18 months 1 2
Other 2b 2c
Patient status (4-year minimum follow-up), n
Off treatment 14 14
Alive 8 10
Dead 6 4
On treatment 3 4
% Mutation detected at trigger plus molecular response at last analysis 90% G250Ed; 0.02% BCR-ABL1IS 80% F359Id; 1.03% BCR-ABL1IS
40% T315Id; 0.039% BCR-ABL1IS 100% G250Ed; 11.3% BCR-ABL1IS
80% T315Id; 0.013% BCR-ABL1IS 90% G250Ed; 7.7% BCR-ABL1IS
20% F359Vd; 20.5% BCR- ABL1IS
Abbreviations: AP/BP, accelerated phase/blast phase; cCCyR, conﬁrmed complete cytogenetic response; CCyR, complete cytogenetic response; CHR, complete
hematologic response; DASISION, Dasatinib versus Imatinib Study in Treatment-Naive CML-CP; IS, international scale; MMR, major molecular response; MCyR,
major cytogenetic response; PCyR, partial cytogenetic response; WBC, white blood cell. aPatients may have had multiple events. bOne no CyR, one lost CCyR.
cOne poor/noncompliance, one patient request. dEstimated percentage of the mutation quantiﬁed in the sample.
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Of note, the effectiveness of dasatinib against P-loop mutations
varies: not all patients with P-loop mutations at the time of
imatinib discontinuation have improved responses with
dasatinib,11,41,42 and P-loop mutations have been shown to
emerge during second-line treatment with dasatinib, including
G250E, Q252H and L248V.3,34,40 Hence, the detection of a G250E
mutation in the dasatinib arm is not surprising, and the absence of
other P-loop mutants could be because of the small number of
patients with mutations identiﬁed.
In this analysis, the T315I mutation was identiﬁed in the
dasatinib arm (n= 11) but not the imatinib arm (n= 0). The
lack of T315I mutations in the imatinib arm of DASISION is
inconsistent with other reports, including the ENESTnd (Evaluating
Nilotinib Efﬁcacy and Safety in Clinical Trials–Newly Diagnosed
Patients) trial.7–11,25,26,43 With 2 and 3 years of follow-up in
ENESTnd, a similar number of patients had a T315I mutation in
the nilotinib and imatinib arms of the study (nilotinib 300mg
twice daily, n= 3; nilotinib 400mg twice daily, n= 2; imatinib
400mg once daily, n=3).25,26 However, differences in methodology,
patient population, small numbers and geographical distribution
between DASISION and ENESTnd make interpretation of cross-
study comparisons difﬁcult.43 Mutation data from ongoing ﬁrst-line
trials by MD Anderson Cancer Center (CA180-040; NCT00254423)44
and the Southwest Oncology Group (SWOG S0325; NCT00070499)45
are expected to provide additional information regarding the
development of mutations in patients with newly diagnosed CML-
CP treated with dasatinib.
One hypothesis for the greater number of T315I mutations
detected with dasatinib (n= 11) compared with imatinib (n= 0)
derives from differences in competitive advantage between
mutant clones observed in in vitro cell assays. Select mutant
clones (for example, P-loop mutations Y253F, E255K) were found
to have higher transformation potency and proliferation rate
compared with T315I, even in the absence of BCR-ABL1
inhibitors.46 Assuming that imatinib has lower activity against
these mutations compared with dasatinib,1,24,34,41,47 mutant
clones with select P-loop mutations may expand more rapidly
than clones with the T315I mutation when exposed to imatinib
compared with dasatinib.
Consistent with this idea, some P-loop mutations have been
shown to arise faster during imatinib treatment than the T315I
mutation,48 and T315I is less common than all P-loop mutations in
CML-CP patients with imatinib resistance.11,42,47–49 In addition,
dasatinib suppresses P-loop mutations to a greater extent than
T315I;34,50–53 therefore, T315I may be able to develop during
dasatinib treatment with relatively little competition from rapidly
proliferating clones.
Patients with mutations in DASISION typically had a poor
outcome, with high rates of discontinuation (82% dasatinib, 78%
imatinib), transformation (24 and 17%) and death (35 and 22%) by
4-year minimum follow-up. The majority of mutations were
identiﬁed early, usually within the ﬁrst 12 months of treatment
(dasatinib: 65%; range, 3–30 months; imatinib: 67%; range,
5–36 months).
Despite the fact that mutations were detected in a small
percentage of patients considered to be more likely to develop
mutations, the data from the DASISION 3-year mutational analysis
reported here suggest that patients with CML-CP who fail to
achieve and maintain treatment response at key milestones
should be considered for mutation screening. This is consistent
with current CML treatment guidelines.12,31,54 Recent CML guide-
line updates from the National Comprehensive Cancer Network
and recommendations from ELN advise mutational analysis be
performed for patients with inadequate molecular or cytogenetic
response.12,31,54 The recent CML recommendations also suggest
that patients with an inadequate response or treatment failure
(inclusive of mutation development) may be considered for an
alternative treatment.
Mutational testing is anticipated to become more widely used
to select second-line treatment in the community setting,
especially with the approval of ponatinib for treatment of
patients with CML or Ph+ acute lymphoblastic leukemia with
resistance or intolerance to prior tyrosine-kinase inhibitor
therapy. Ponatinib has demonstrated activity against T315I/A
in preclinical assays,55 and patients with the T315I mutation
respond well to ponatinib, unlike patients with T315I treated
with other BCR-ABL1 inhibitors.15,17 In addition, with the
introduction of generic imatinib into the market in 2016,
choosing the most appropriate second-line tyrosine-kinase
inhibitor for patients, based on factors such as mutation status,
will become increasingly important. Allowing physicians the
option to choose the most suitable second-line therapy may
ensure improved outcomes and decreased health-care costs.56
More sensitive detection methods (for example, next-generation
sequencing) may allow mutations that were not evident through
conventional sequencing to be detected following a signiﬁcant
rise in BCR-ABL1 levels;2 however, further data are needed to
determine the clinical relevance of low-level mutations for
patient outcomes.2,40,57–60
Mutational testing provides arguably the most important
measure for treatment selection in patients with CML, especially
when selecting an alternative therapy because of current
treatment failure. In patients with less-resistant mutations, other
factors, such as patient comorbidities, the potential for cross-
intolerance and adherence, should also be considered to ensure
patients achieve good long-term outcomes.








Euro (Hasford) score, n (% of patients)a
Low (p780) 5 (29) 6 (33)
Patients at risk 86 87
Intermediate (4780 to p1480) 5 (29) 8 (44)
Patients at risk 124 213
High (41480) 7 (41) 4 (22)
Patients at risk 49 50




Best molecular response, n
MMR 2 1
BCR-ABL1 p10% at 3 months 10b 6c
Treatment milestone
cCCyR by 12 months
Achieved 6 4
Not achieved 11 14
MMR at 12 months
Achieved 0 0
Not achieved 17 18
Abbreviations: cCCyR, conﬁrmed complete cytogenetic response; CCyR,
complete cytogenetic response; MMR, major molecular response; PCyR,
partial cytogenetic response. aInvestigator-reported Euro (Hasford)
risk score. bBCR-ABL1 transcript levels not available for one patient.
cThree-month BCR-ABL1 transcript levels not available in two patients.
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